News

Age-related Eye Disease Heightens Parkinson’s Risk, Study Suggests

People with age-related macular degeneration, an eye disease that blurs central vision, may have a higher risk of developing Parkinson’s disease, a Taiwanese population‐based retrospective study suggests. The study, ‘Increased risk of Parkinson’s disease among patients with age-related macular degeneration,” was published in the journal BMC Ophthalmology. Age-related…

Lifestyle Factors, Medical Problems May Impact Early-stage Cognition

Lifestyle factors and co-existing medical conditions influence cognition in people in the early stages of Parkinson’s disease, with physical exercise and cognitive stimulation shown to have a protective effect, a large study revealed. High blood pressure, diabetes, and psychiatric problems were found to have a negative impact on cognitive…

Inflammatory Bacteria in Nose Linked to Parkinson’s Risk

People with Parkinson’s disease tend to have high numbers of pro-inflammatory bacteria in their noses, according to a new study. Researchers think these bacteria may be a trigger for inflammation in the brain, which could help to set the stage for the development of Parkinson’s. The study, “Deep…

Pseudobulbar Affect May Be More Common in Patients Than Thought

More people with Parkinson’s disease than previously estimated experience pseudobulbar affect, and its emotional outbursts can be especially common in patients with depression, a study in patients at a single U.S. institution reported. “Our data suggest that the prevalence of PBA [pseudobulbar affect] is possibly higher in the PD…

No Association Between Gout and Parkinson’s in Korean Study

Gout does not increase the risk of developing Parkinson’s disease, according to an analysis based on insurance data in Korea. The analysis indicates, however, that people who have had a stroke and those with high blood pressure might have a higher Parkinson’s risk. Results were published in the study “…

Apomorphine Infusion Device Again Before FDA for Approval

Supernus Pharmaceuticals has again applied to the U.S. Food and Drug Administration (FDA) requesting that its apomorphine infusion device (SPN-830), allowing continuous treatment of Parkinson’s disease motor symptoms, be approved. “SPN-830 is an important product candidate which, if approved by the FDA, represents a novel approach for PD…